Basit öğe kaydını göster

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

dc.contributor.authorSo, TMK
dc.contributor.authorCakaloglu, Y
dc.contributor.authorGerken, G
dc.contributor.authorSimon, C
dc.contributor.authorJanssen, HLA
dc.contributor.authorvan Zonneveld, M
dc.contributor.authorFlink, HJ
dc.contributor.authorVerhey, E
dc.contributor.authorSenturk, H
dc.contributor.authorZeuzem, S
dc.contributor.authorAkarca, US
dc.contributor.authorSchalm, SW
dc.contributor.authorHansen, BE
dc.contributor.authorde Man, RA
dc.date.accessioned2021-03-02T22:21:49Z
dc.date.available2021-03-02T22:21:49Z
dc.date.issued2005
dc.identifier.citationvan Zonneveld M., Flink H., Verhey E., Senturk H., Zeuzem S., Akarca U., Cakaloglu Y., Simon C., So T., Gerken G., et al., "The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, cilt.21, sa.9, ss.1163-1171, 2005
dc.identifier.issn0269-2813
dc.identifier.otherav_0c3ad19c-21b5-48fd-a03e-068dcd0c41b0
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/13877
dc.identifier.urihttps://doi.org/10.1111/j.1365-2036.2005.02453.x
dc.description.abstractBackground: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri
dc.subjectTemel Eczacılık Bilimleri
dc.subjectEczacılık
dc.subjectGastroenteroloji-(Hepatoloji)
dc.titleThe safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation
dc.typeMakale
dc.relation.journalALIMENTARY PHARMACOLOGY & THERAPEUTICS
dc.contributor.department, ,
dc.identifier.volume21
dc.identifier.issue9
dc.identifier.startpage1163
dc.identifier.endpage1171
dc.contributor.firstauthorID175191


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster